Nafoxadol: Difference between revisions
CSV import |
CSV import |
||
| Line 45: | Line 45: | ||
[[Category:Piperazines]] | [[Category:Piperazines]] | ||
[[Category:Serotonin receptor modulators]] | [[Category:Serotonin receptor modulators]] | ||
<gallery> | |||
File:Nafoxadol.svg|Nafoxadol | |||
</gallery> | |||
Latest revision as of 01:30, 20 February 2025
| Nafoxadol | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 82426-48-6 |
| PubChem | 65860 |
| DrugBank | |
| ChemSpider | 59273 |
| KEGG | D05199 |
Nafoxadol is a pharmaceutical compound that has been studied for its potential use as an analgesic, particularly in the management of pain. It belongs to the class of drugs known as piperazine derivatives and has been investigated for its effects on the central nervous system.
Pharmacology[edit]
Nafoxadol acts primarily as a serotonin receptor modulator. It has been shown to interact with various subtypes of serotonin receptors, which are involved in the modulation of pain perception. The exact mechanism by which nafoxadol exerts its analgesic effects is not fully understood, but it is believed to involve the modulation of neurotransmitter release in the central nervous system.
Clinical Use[edit]
Nafoxadol has been studied in clinical trials for its potential use in treating different types of pain, including neuropathic pain and chronic pain. However, as of the latest updates, it has not been approved for clinical use in any major market. The results of clinical trials have been mixed, with some studies showing promising results while others have not demonstrated significant efficacy compared to placebo.
Side Effects[edit]
The side effects of nafoxadol are similar to those of other drugs that modulate serotonin receptors. Common side effects may include nausea, dizziness, and headache. More serious side effects could include serotonin syndrome, especially if used in combination with other serotonergic drugs.
Research and Development[edit]
Research into nafoxadol is ongoing, with studies focusing on its pharmacokinetics, pharmacodynamics, and potential therapeutic applications. The development of nafoxadol has been hampered by the complexity of its interactions with multiple serotonin receptor subtypes, which complicates the prediction of its effects in different patient populations.
Also see[edit]
References[edit]
<references group="" responsive="1"></references>
-
Nafoxadol
